Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g. NEAR(recruit, professionals, 20)).
Finds documents with the search term in word versions or composites. The asterisk * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g. lightweight*, *lightweight, *lightweight*).
Head and Neck Squamous Cell Carcinoma (HNSCC) is a highly aggressive malignant tumor. Traditional therapeutic approaches have limited efficacy in locally advanced HNSCC patients, and neoadjuvant immunotherapy has emerged as a new hope. However, the current outcomes of neoadjuvant immunotherapy for HNSCC are not yet optimal and urgently need improvement. This article comprehensively reviews the clinical research progress of neoadjuvant immunotherapy in the field of HNSCC treatment. By integrating perspectives from the regulatory mechanisms of the immune microenvironment, we propose future research directions for enhancing the efficacy of neoadjuvant immunotherapy for HNSCC patients.
CRC remains a major global health burden, but advances in screening, treatment, and lifestyle-based prevention continue to reshape clinical practice. Gain insights into how the latest research can be leveraged to optimize patient care across the CRC continuum.
Watch it live: Thursday 11 December 2025, 18:00-19:30 (CET)
Are you up to date on targeted therapies for relapsed/refractory AML?
Join Prof. Amer Zeidan and his expert guests to hear about innovations in molecular testing, emerging therapies, and IDH-targeted treatments, and get practical advice for improving your patient care.
Supported by: independent educational grant from Rigel